Coverage clusters in regulation, which accounts for 2 of those 3, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 2.7 original sources each against 4.3 for the same window. Emily Felix is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Biogen
Coverage clusters in regulation, which accounts for 2 of those 3, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 2.7 original sources each against 4.3 for the same window. Emily Felix is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. Across a 135-day span, the pace is roughly 0.2 stories per week. Their average consequence score of 5.7 runs below the beat's 6.3 for that window. Biogen appears in 3 tracked Healthcare stories published from March 23, 2026 through August 4, 2026.
Stories tracked
3
Per week
0.2
Sources per story
2.7
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 398 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Biogen. Shared-story counts are live from our verified record — not editorial picks.
Supernus Pharmaceuticals is acquiring Indivior in an all-stock deal, assembling a portfolio of 11 FDA-approved CNS treatments. The merger targets $125 million in annual cost synergies and expands the company's footprint in neurology, addiction, and psychiatry. Meanwhile, Q2 revenue jumped 32% to $219 million, but a surprise net loss of $58.1 million casts a shadow over short-term integration risks.
A woman with Friedreich’s ataxia sues the HSE over an unacceptably prolonged reimbursement decision for omaveloxolone, a treatment that could slow her decline and that is already standard care in 12 other European countries.
Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for a rare genetic muscle disease. This landmark policy shift aims to identify affected infants at birth, allowing for immediate intervention and treatment before the onset of irreversible physical symptoms.
